Top 10 Companies in Antibody Market - Company Overview, Recent Developments and SWOT Analysis 2030
The Antibody Market is driven by rising number of research and development activities by various biopharmaceutical and pharmaceutical companies to develop innovative products. Antibodies are proteins that are produced in response to specific antigens which are also known as immunoglobulin. Several product launches shown steady growth for this market. Effective harmonization of product development, registration guidelines and approval are also key factors to boost the market. Increase demand for therapeutic antibodies, including monoclonal and polyclonal antibodies is the key factor driving the market. Many pharmaceutical and biotechnology companies are focusing on developing advanced antibodies to treat chronic disease like cancer, rheumatic heart disease and arthritis. Patent expiry of several successful monoclonal antibodies shortly also drives the antibody market.
Antibody Market is estimated to be US$ 393.6 billion by 2030 with a CAGR of 11.5% during the forecast period.
Here are the top 10 companies operating in Antibody Market
Founded in: 1886
Headquarter: New Brunswick, New Jersey, U.S.
Number of Employees: 144,500 (2021)
Annual Revenue in USD: 93.78 billion (2021)
Johnson & Johnson is a public company which is headquartered in New Brunswick, New Jersey, U.S. Johnson & Johnson is an American multinational company. Johnson & Johnson is the developer of pharmaceutical products, medical devices, consumer packaged goods, etc. Johnson & Johnson is involved in various business sectors like in pharmaceutical sector includes – Immunology, neuroscience, cardiovascular & metabolic disease, infectious disease & vaccines, oncology, pulmonary hypertension, etc. Medtech sector includes – Orthopaedics Surgery, interventional solutions, etc. Consumer health sector includes – Medicines, baby care, women’s health, oral care, wound care, skin health, etc.
Founded in: 1896
Headquarter: Basel Switzerland
Number of Employees: 100,920 (2021)
Annual Revenue in CHF: 62.80 billion (2021)
F. Hoffmann-La Roche AG, is known as Roche. Roche is the Swiss multinational healthcare company. Roche operates under two sectors like diagnostics and pharmaceuticals. Roche has become the fifth largest pharmaceutical company in the world. Roche is the leading provider of cancer treatments worldwide. Roche is the developer of drugs used in cancer treatment, metabolic disease treatment, and virus disease treatment. Roche is the world’s largest spender in pharmaceutical research & development.
Key Highlights:
- In October 2022, Roche has launched new SARS-CoV-2 Rapid Antibody Test 2.0 for use by healthcare professionals. The newly launched test has 95.83% of sensitivity & 100% of specificity when it is performed after 15 days of symptom onset.
Founded in: 2013
Headquarter: North Chicago, Illinois, U.S.
Number of Employees: 50,000 (Jan 2021)
Annual Revenue in USD: 56.20 billion (2021)
AbbVie Inc., is a public company. AbbVie is an American biopharmaceutical company. AbbVie is the discoverer and deliverer of transformational medicines and products in various therapeutic areas like immunology, virology, oncology, women’s health, eye care, neuroscience, allergan aesthetics, etc.
Key Highlights:
- In October 2022, AbbVie has announced the acquisition of UK based DJS Antibodies for $255m. The acquisition of company will help in delivering new capabilities for enhancing current antibody research activities which will give opportunity for strengthening immunology portfolio by providing strongest foothold for expanded R&D in dynamic bioscience hub in Oxford, UK.
Founded in: 1996
Headquarter: Basel Switzerland and Cambridge, Massachusetts, U.S.
Number of Employees: 110,000 (2021)
Annual Revenue in USD: 52.88 billion (2021)
Novartis AG, is a Swiss-American multinational company. Novartis has become the largest pharmaceutical company in the world. Novartis is the manufacturer of drugs. Novartis offer products in vaccines, generic drugs, pharmaceutical drugs, diagnostics, animal health products, counter drugs, contact lenses, etc.
Key Highlights:
- In March 2022, Novartis ‘Pluvicto’ is approved by FDA as first targeted radioligand therapy for use in treating progressive, positive metastatic castration-resistant prostate cancer which has spread to other parts of body. ‘Pluvicto’ has become the important clinical advancement for patient with progressing mCRPC.
Founded in: 1887
Headquarter: New York, U.S.
Number of Employees: 32,200 (2021)
Annual Revenue in USD: 46.39 billion (2021)
Bristol Myers Squibb Company, is a public company. Bristol Myers Squibb is an American multinational pharmaceutical company. Bristol Myers Squibb is the manufacturer of biologics, pharmaceutical products in various sector like cardiovascular disease, cancer, diabetes, hepatitis, psychiatric disorders, rheumatoid arthritis, HIV-AIDS, etc.
Key Highlights:
- In March 2021, Bristol Myers Squibb has announced the RELATIVITY-047, a trial for determining Anti-LAG-3 Antibody Relatlimab & Opdivo (nivolumab) in patients who are previously untreated with metastatic/unresectable melanoma. The trial has met the primary endpoint of PFS (progression free survival) and fixed-dose combination was well tolerated.
Founded in: 1973
Headquarter: Paris, France
Number of Employees: 95,442 (2021)
Annual Revenue in EUR: 39.18 billion (2021)
Sanofi S.A. is a French multinational company. Sanofi is the pharmaceutical and healthcare company. Sanofi is the manufacturer and marketer of pharmaceutical drugs, vaccines, generic drugs, counter drugs, diagnostic products, animal health products, contact lenses, etc. Sanofi covers major therapeutic areas like diabetes, oncology, cardiovascular diseases, thrombosis, central nervous system, vaccines, internal medicine, etc.
Founded in: 1876
Headquarter: Indianapolis, Indiana, U.S.
Number of Employees: 35,000 (2021)
Annual Revenue in USD: 28.32 billion (2021)
Eli Lilly and Company, is an American pharmaceutical company. Eli Lilly and Company sold its products in over 125 countries. Eli Lilly and Company offer pharmaceutical drugs. Eli Lilly and Company is known for its clinical depression drugs. Eli Lilly is also the developer of vaccines, biosimilar insulin product, etc.
Key Highlights:
- In February 2022, U.S. FDA has issued an Emergency Use Authorization (EUA), for Lilly’s ‘bebtelovimab’ which is an antibody that identifies neutralization against Omicron variant. Newly developed ‘bebtelovimab’ will be used in treating mild to moderate COVID-19 in pediatric and adults patients with positive results of SARS-CoV-2 viral testing.
Founded in: 1980
Headquarter: Thousand Oaks, California, U.S.
Number of Employees: 24,200 (December 2021)
Annual Revenue in USD: 25.98 billion (2021)
Amgen Inc., is a public company, Amgen is the American multinational biopharmaceutical company and world’s largest independent biotechnology company. Amgen is focused on biochemistry and molecular biology. Amgen provides healthcare business which is based on recombinant DNA technology.
Key Highlights:
- In August 2022, Amgen Inc., announced the agreement to acquire ChemoCentryx for $52 per share in cash, by representing enterprise value of approx. $3.7 billion. ChemoCentryx ‘TAVNEOS’ has indicated as adjunctive treatment of adult patients with severe ANCA (anti-neutrophil cytoplasmic autoantibody) associated vasculitis in combination with standard therapy that includes glucocorticoids.
Founded in: 1978
Headquarter: Cambridge, Massachusetts, U.S.
Number of Employees: 9,100 (2020)
Annual Revenue in USD: 10.98 billion (2021)
Biogen Inc., is a public company. Biogen is an American multinational biotechnology company. Biogen is the discovere, developer, and deliverer of therapies for treating neurological diseases in patient worldwide. Biogen also offer therapeutic products used in treating Alzheimer’s disease, relapsing form of multiple sclerosis, hemophilia A, Psoriasis, inflammatory bowel disease, leukemia, rheumatoid arthritis, hemophilia B, etc.
Key Highlights:
- In September 2022, Biogen Inc., has announced the positive topline results from Eisai’s large global phase 3 confirmatory clarity AD clinical trial of lecanemab which is an investigational anti-amyloid beta protofibril antibody used in treatment of mild cognitive impairment caused due to Alzheimer’s disease and mild Alzheimer’s disease with confirmatory presence of amyloid pathology in brain. Thus, lecanemab has met the primary endpoint and secondary endpoint with highly statistically significant results.
Founded in: 1781
Headquarter: Nihonbashi, Chuo, Tokyo, Japan
Number of Employees: 49,578 (2019)
Annual Revenue in JPY: 3,197.81 billion (2021)
Takeda Pharmaceutical Company Limited, is a Japanese multinational pharmaceutical company. Takeda Pharmaceutical is the largest pharmaceutical company in Asia. Takeda Pharmaceutical is focused on neuroscience, oncology, gastroenterology, rare diseases, vaccines and plasma-derived therapies. Takeda Pharmaceutical maintains research and development sites in United States and Japan.
Key Highlights:
- In January 2022, Takeda Pharmaceutical Company Limited made announcement to acquire Adaptate Biotherapeutics which is a UK company focused on developing of antibody-based therapeutics for modulation of gamma delta and variable data T cells. The company’s acquisition will help in strengthening immune-oncology R&D efforts for life-transforming medicines for patients with cancer. Thus, the acquisition has added Adaptate’s Novel Antibody-based gamma delta T cell engager platform to Takeda’s Immuno-oncology portfolio to built around the innate immune system.